ArticleNeuro-oncology2014
Progression-free survival: too much risk, not enough reward?
Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?Neuro-oncology · 2018Pooled it
- Novel Clinical Trial Designs in Neuro-Oncology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Review
- Review
- Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma.JCO precision oncology · 2019Article
- The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.Neuro-oncology · 2018Review
- Unbiased estimation for response adaptive clinical trials.Statistical methods in medical research · 2017Article
- Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.Neuro-oncology · 2017Article
- Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.Neuro-oncology · 2017Article
- Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.Neuro-oncology · 2015Article
- Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma.Neuro-oncology · 2015Article
- Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.Neuro-oncology · 2015Review
- Biostatistical benchmarking of neuro-oncology trials.Neuro-oncology advancesReview
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.